AUS
NZ
UK
CA
USA
IND
Highlights
- (ZIP) sees a 27.9% price decline in 2025, while revenue continues to grow.
- (COH) trading 7.3% above its 52-week lows, maintaining global leadership in hearing implants.
- Both stocks currently trade below their 5-year historical price-sales ratios.
The Australian stock market has witnessed notable shifts in several sectors this year, with (ZIP) and (COH) standing out for different reasons. While (ZIP) has experienced a significant price dip, (COH) is making strides in maintaining its industry leadership. Let's explore how these two companies are performing and what their current valuations suggest about their potential.
(ASX:ZIP) Navigating Market Challenges
Founded in 2013, (ZIP) operates in the fintech space, providing a buy-now-pay-later (BNPL) platform that allows consumers to make immediate purchases with installment-based repayments. This model has become a preferred payment alternative, particularly in the retail sector.
Revenue for (ZIP) has shown consistent growth over the last three years, despite the company's share price seeing a 27.9% decline since the start of 2025. One valuation metric to consider is the price-to-sales ratio, which currently stands at 3.22x, below its five-year average of 5.81x. This may indicate that the stock is trading lower than its historical norm, influenced by either price adjustments or increasing revenues.
(ASX:COH) Strengthening Its Market Position
Established in 1981, (COH) is a globally recognized medical device company specializing in hearing implants. It has delivered over 750,000 implantable devices worldwide and employs over 5,000 professionals across more than 50 countries.
Currently, (COH) is trading 7.3% above its 52-week lows, reflecting resilience in its market segment. Its price-to-sales ratio stands at 8.03x, compared to its five-year average of 9.18x. This suggests that shares are being traded below historical levels, which can provide an interesting perspective for those analyzing long-term industry trends.
Assessing the Market Outlook
Both (ZIP) and (COH) currently trade below their historical price-sales ratios, indicating they are valued lower compared to their past trends. However, valuation metrics should be just one part of broader market analysis, as factors like revenue growth, industry trends, and macroeconomic conditions also play a crucial role in shaping long-term performance.
With fintech and healthcare continuing to evolve, the performance of (ZIP) and (COH) will remain under watch in the coming months. Observing financial trends, business strategies, and sector developments will provide further insights into these two ASX-listed companies.
